Article
Obstetrics & Gynecology
Sharon Treger, Shanny Ackerman, Victoria Kaplan, Shourouk Ghanem, Yona Nadir
Summary: The study shows that progestin increases heparanase level and procoagulant activity through the estrogen receptor, with the effect depending on the type of progestin. This can impact coagulation system activation and increase thrombotic risk.
HUMAN REPRODUCTION
(2021)
Review
Endocrinology & Metabolism
Kelly L. Klump, Alaina M. Di Dio
Summary: Endogenous ovarian hormones may increase the risk of binge eating in females through gene x hormone interactions and hormonally induced increases in genetic influences. Combined oral contraceptives (COCs), which mimic the riskiest hormonal environment for binge eating, are commonly used by women. Preliminary studies suggest that COCs may increase the risk of binge eating and related phenotypes, especially in genetically vulnerable women. Larger and more systematic studies are needed to explore the relationship between COCs and binge eating, with the goal of advancing personalized medicine.
FRONTIERS IN NEUROENDOCRINOLOGY
(2022)
Article
Medicine, General & Internal
Maria Aranzazu Martin Iglesias, Rosa Garcia Rodriguez, Alberto Palacios Canas, Jaime Vinicio Meneses Sotomayor, Miriam Clar Castello, Francisco Feo Brito
Summary: This study evaluated a new treatment option for LTP syndrome, which involved SLIT-peach followed by OIT with commercial peach juice. The results demonstrated that this protocol was safe and effective, improving the quality of life for patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Hematology
Leslie Skeith, Gregoire Le Gal, Marc A. Rodger
Summary: Exogenous hormone therapies like combined oral contraceptives (COC) and hormone replacement therapy (HRT) can increase blood hypercoagulability and the risk of venous thromboembolism (VTE). Controversy exists on the strength of this provoking risk factor and how it may synergize with other risk factors. Reviewing the latest literature on COC and HRT usage can provide guidance for anticoagulation duration decisions and future research direction.
THROMBOSIS RESEARCH
(2021)
Review
Endocrinology & Metabolism
Emily N. Hilz
Summary: Hormonal contraceptives alter neurobehavioral outcomes in users, but research in this area is limited. Animal models can provide insights into the mechanisms of different hormonal contraceptives, but the models are not well-established.
FRONTIERS IN NEUROENDOCRINOLOGY
(2022)
Article
Gastroenterology & Hepatology
Sherif Saleh, Benjamin D. Liu, Sophie Trujillo, Charles Thomas, Ronnie Fass
Summary: This study demonstrates that hormone replacement therapy and combined oral contraceptives are associated with an increased risk of gastroesophageal reflux disease (GERD), while the commonly used progesterone-based contraceptive Nexplanon has a limited protective effect against GERD.
NEUROGASTROENTEROLOGY AND MOTILITY
(2023)
Article
Sport Sciences
Laura Barba-Moreno, Rocio Cupeiro, Nuria Romero-Parra, Xanne A. K. Janse de Jonge, Ana B. Peinado
Summary: This study investigated the effects of menstrual cycle phases and oral contraceptive use on cardiorespiratory responses during exercise in women. The results showed that certain phases of the menstrual cycle and oral contraceptive cycle could lead to increased ventilatory parameters, indicating lower cardiorespiratory efficiency. However, these differences had limited clinical significance, and the impact of the menstrual cycle on submaximal exercise was minimal.
JOURNAL OF STRENGTH AND CONDITIONING RESEARCH
(2022)
Article
Oncology
Anuradha Sharma, Indu Sharma
Summary: Progestin-only based oral contraceptives, also known as 'minipills', are widely used for preventing unintended pregnancy and treating various conditions. However, there is limited research on the relationship between progestin and ovarian cancer. This study aimed to evaluate the potential of synthetic progestin Norethindrone (NET) in preventing epithelial ovarian cancer. The results showed that NET treatment inhibited cell growth, induced cell cycle arrest, increased reactive oxygen species (ROS) levels, triggered cell death, and inhibited cell migration. Furthermore, NET regulated the expression of genes related to angiogenesis, inflammation, proliferation, metastasis, and tumor suppression. These findings suggest that Norethindrone may have a chemo-preventive effect against ovarian carcinogenesis and warrant further investigation for potential changes in prescription practices or health-related advice for women.
Article
Clinical Neurology
Therese Johansson, Philip Fowler, Weronica E. Ek, Alkistis Skalkidou, Torgny Karlsson, Asa Johansson
Summary: The use of oral contraceptives and hormone replacement therapy is associated with an increased risk of stroke, especially during the first year of use. This study provides new insights on the effects of hormone exposure on stroke risk and shows significant effects during the beginning of treatment.
Article
Obstetrics & Gynecology
C. Lundin, A. Wikman, E. Lampa, M. Bixo, K. Gemzell-Danielsson, P. Wikman, R. Ljung, I. Sundstrom Poromaa
Summary: The study found that women using combined oral contraceptives had a lower risk of depression compared to non-users, while women using oral progestogen-only products had almost no increased risk.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sabina Cauci, Serena Xodo, Cinzia Buligan, Chiara Colaninno, Mattia Barbina, Giuseppe Barbina, Maria Pia Francescato
Summary: This study found that oral contraceptive users had significantly elevated oxidative stress and increased levels of serum hsCRP, indicating signs of low-grade chronic inflammation. Additionally, there was a strong positive correlation between oxidative stress and hsCRP, which is significant in assessing the risk for future cardiovascular diseases.
Article
Obstetrics & Gynecology
Lina El Taha, Antoine Abu Musa, Dalia Khalifeh, Ali Khalil, Sehrish Abbasi, Joseph Nassif
Summary: The study showed that dienogest and oral contraceptives have comparable efficacy in relieving endometriosis-associated pelvic pain and improving health-related quality of life. Dienogest had fewer side effects and better safety and tolerability compared to oral contraceptives.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
(2021)
Article
Hematology
Jean-Christophe Gris, Chloe Bourguignon, Sylvie Bouvier, Eva Nouvellon, Jeremy Laurent, Antonia Perez-Martin, Eve Mousty, Mariya Nikolaeva, Jamilya Khizroeva, Victoria Bitsadze, Alexander Makatsariya
Summary: This study retrospectively examined thrombotic outcomes during pregnancy following an initial combined oral contraceptive (COC)-associated venous thromboembolic (VTE) event and analyzed factors associated with recurrence. The results showed a significant rate of VTE recurrence during pregnancy and puerperium, despite thromboprophylaxis treatment with low-molecular-weight heparin.
THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Obstetrics & Gynecology
K. Gemzell-Danielsson, D. Apter, J. Zatik, S. Weyers, T. Piltonen, L. Suturina, I Apolikhina, M. Jost, M. D. Creinin, J-M Foidart
Summary: The study confirmed that E4/DRSP provides effective contraception, a predictable bleeding pattern, and a favorable safety profile. The proportion of participants who discontinued the study was relatively low, with overall satisfactory results.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2022)
Article
Clinical Neurology
Pelin Batur, Meng Yao, Julia Bucklan, Payal Soni, Aarushi Suneja, Ruth Farrell, Maryann Mays
Summary: This study aims to investigate the impact of factors such as estrogen dose and migraine history on ischemic stroke risks associated with using combined hormonal contraceptive (CHC). The use of CHC has been restricted in individuals with migraine with aura due to concerns about stroke risk.
